Compare DuPont de Nemours Inc (DD) vs Novartis AG (NVS) Price & Performance

DuPont (DD) trades at $130.53, down 0.42% on the day, with a neutral technical signal and bearish moving average trend. The company reported a net loss of $779 million in 2025 despite beating EPS estimates in recent quarters, with revenue declining to $6.85 billion. Analyst consensus is bullish with 59% buy ratings, though the consensus price target of $95 is below the current price. Recent news highlights innovation in Tyvek materials and digital tools, alongside legal settlements over PFAS contamination.

The outlook is mixed: strong analyst support and product innovation offer upside, but recent profitability challenges, high P/E ratio, and legal liabilities pose risks. Earnings growth and margin recovery are critical for sustaining investor confidence amid volatile cash flows and competitive pressures.

Novartis (NVS) trades at $143.22, down 0.04% on the day, near the analyst consensus price target of $146. The stock shows mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 revenue of $56.67B and net income of $13.98B, with a robust net margin of 24.67%. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though this follows clinical setbacks in other drug programs.

The outlook is cautiously optimistic. The Abogen deal expands the pipeline in autoimmune diseases, a growth area, and analyst consensus leans Hold with a slight upside to the price target. Key risks include integration challenges from recent acquisitions, pipeline volatility after trial failures, and investor scrutiny over M&A strategy. Earnings momentum is mixed, with a recent beat in Q2 but a miss in Q1, requiring consistent execution to justify current valuations.